Genentech Newswire

Comprehensive Real-Time News Feed for Genentech.

Results 1 - 20 of 312 in Genentech

  1. Sandoz Was Disinvited to the Patent Dance: The Federal Circuit's...Read the original story w/Photo

    9 hrs ago | JD Supra

    ... was proper under the Declaratory Judgment Act, 28 U.S.C. 2201, based on principles set out in MedImmune, Inc. v. Genentech, Inc. , 549 U.S. 118 (2007). According to Sandoz, the MedImmune test would be satisfied as to either party in a proceeding ...

    Comment?

  2. Endophthalmitis Outbreak Associated with Repackaged BevacizumabRead the original story

    11 hrs ago | Centers for Disease Control and Prevention

    ... with repackaged bevacizumab occurred during February-March 2013 in Georgia and Indiana, USA. Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA, USA) is a vascular endothelial growth factor inhibitor that is approved by the US Food and ...

    Comment?

  3. Bellicum Leaps On Biotech IPO, Setting Stage For JunoRead the original story

    Yesterday | Investor's Business Daily

    ... among institutional investors over Juno was at a level he hadn't seen since the IPO of cancer drug developer Genentech in July 1999, when it was spun out of Roche Holding. That $1.94 billion IPO sparked a biotech bull market. Roche retained a ...

    Comment?

  4. Gilead raids Genentech to add to cancer ranksRead the original story w/Photo

    Monday Dec 15 | Business Journal

    Gilead Sciences Inc. , coming off its first cancer drug approval and with more in its portfolio, hired Dr. Philippe Bishop away from Genentech Inc. to head its cancer drug programs. Bishop since 2007 had been vice president of oncology product development at South San Francisco-based Genentech, running dozens of drugs through hundreds of clinical trials.

    Comment?

  5. Company seeks approval for skin cancer drugRead the original story w/Photo

    Monday Dec 15 | Fox News

    A Roche Holding AG subsidiary submitted a drug for treating people treating patients with an advanced form of skin cancer to U.S. regulators, the company said Monday, starting the process for potential approval of the therapy. Genentech, Roche's U.S.-based biotechnology subsidiary, said it had submitted a new drug application for its cobimetinib treatment to be used in combination with the existing Zelboraf treatment for patients with mutation-positive advanced melanoma.

    Comment?

  6. Insmed Appoints Myrtle Potter to its Board of DirectorsRead the original story

    Monday Dec 15 | Freshnews

    ... firm she founded in 2005. She was previously the President of Commercial Operations and Chief Operating Officer of Genentech and had extensive experience in senior operating roles at Bristol-Myers Squibb and Merck. "It is with great pleasure that we ...

    Comment?

  7. Genentech R&D chief Richard Scheller to retireRead the original story w/Photo

    Friday Dec 12 | Business Journal

    Genentech's top R&D researcher, Richard Scheller , will retire at the end of the year and be replaced by the biotech giant's head of small molecule discovery. The move could be interesting for a couple of reasons.

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Sunday Dec 14 | Business Wire

    )--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company has submitted a New Drug Application (NDA) for cobimet... )--Regulatory News: Technip (Paris:TEC) (ISIN:FR0000131708) (ADR:TKPPY) annonce aujourd'hui ...

    Comment?

  9. Report Published: "Choroidal Neovascularization - Pipeline Review, H2 2014"Read the original story

    Saturday Dec 13 | PR-inside.com

    ... factors that drove them from pipeline Companies Mentioned in this Report: Affitech A/S, F. Hoffmann-La Roche Ltd., Genentech, Inc., MABLife S.A.S, Navigen Pharmaceuticals, Inc., Promedior, Inc., Regeneron Pharmaceuticals, Inc., Resolvyx ...

    Comment?

  10. While visions of sugarplums danced through their heads [Discovering Biology in a Digital World]Read the original story w/Photo

    Saturday Dec 13 | ScienceBlogs

    ... excess glucose out of our system. This holiday season, we give thanks for insulin and the biotech companies like Genentech that cloned the human gene and began to produce this protein in genetically modified microbes. Today, insulin is one of the ...

    Comment?

  11. Changes In Roche Board Of Directors And Enlarged Corporate Executive CommitteeRead the original story

    Thursday Dec 11 | BioSpace

    ... respectively." Change in the enlarged Corporate Executive Committee Richard Scheller (61), Ph.D., Head of Genentech Research and Early Development (gRED) and member of the enlarged Corporate Executive Committee has decided to retire as of 31 ...

    Comment?

  12. New Market Research Report: Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014Read the original story

    Friday Dec 12 | PR-inside.com

    ... F. Hoffmann-La Roche Ltd., Celsion Corporation, Amgen Inc., Sanofi, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Agenus, Inc., Nemucore Medical Innovations, Inc., Sumitomo Dainippon Pharma Co., Ltd., Lentigen Corporation, Sangamo ...

    Comment?

  13. Roche Names New Genentech ChiefRead the original story w/Photo

    Friday Dec 12 | Wall Street Journal

    Roche Holding AG said Friday it plans to expand its board of directors by two members, as it announced the head of its important Genentech research and development arm will retire. Basel-based Roche said it will nominate Bernard Poussot, the former chief executive of Wyeth Corp., and Richard Lifton, a genetics professor at Yale University's medical school to the board.

    Comment?

  14. Roche says head of Genentech research unit to retireRead the original story

    Thursday Dec 11 | Reuters

    Roche said the head of research operations at its subsidiary Genentech would retire at the end of the year, the latest in a string of executives to leave the Californian biotech unit. The Swiss firm said on Friday Richard Scheller, 61, had decided to retire as head of Genentech Research and Early Development -- known as gRED -- on Dec. 31. Michael D. Varney, who currently leads the company's small molecule drug discovery unit, will take over as head of gRED and become a member of the enlarged corporate executive committee.

    Comment?

  15. Bay Area drivers can't stop barreling into flood watersRead the original story w/Photo

    Thursday Dec 11 | SFGate

    Take Genentech employee Paul Latimer , who is based in Texas but was in the Bay Area for Thursday's big storm. He decided to take his chances rolling a rented Mercedes-Benz through pooled water on a Peninsula street in the morning.

    Comment?

  16. New Market Research Report: Metastatic Melanoma - Pipeline Review, H2 2014Read the original story

    Thursday Dec 11 | PR-inside.com

    ... Company, F. Hoffmann-La Roche Ltd., Vical Incorporated, Amgen Inc., Sanofi, AstraZeneca PLC, GlaxoSmithKline plc, Genentech, Inc., Agenus, Inc., MedImmune, LLC, Merck & Co., Inc., Plexxikon Inc., Delcath Systems, Inc., ZIOPHARM Oncology, Inc., ...

    Comment?

  17. Efficacy and Safety of Omalizumab in Patients with Chronic...Read the original story

    Thursday Dec 11 | The Journal of Investigative Dermatology

    Journal of Investigative Dermatology 135, 67–75; doi:10.1038/jid.2014.306; published online 21 August 2014 Correspondence: Karin Rosén, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, USA.

    Comment?

  18. Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 - New Study ReleasedRead the original story

    Wednesday Dec 10 | PR-inside.com

    ... Bristol-Myers Squibb Company, Johnson & Johnson, Amgen Inc., Sanofi, Eli Lilly and Company, Viralytics Ltd., Genentech, Inc., MedImmune, LLC, Gilead Sciences, Inc., Merck & Co., Inc., Emergent BioSolutions Inc., Infinity Pharmaceuticals, Inc., ...

    Comment?

  19. Sandoz Inc. v. Amgen Inc.Read the original story w/Photo

    Wednesday Dec 10 | JD Supra

    ... to have jurisdiction pursuant to the Declaratory Judgment Act. Quoting the Supreme Court in MedImmune, Inc. v. Genentech, Inc. , 549 U.S. 118 (2007), the Court noted that for there to be a "case-or-controversy," a court must determine "whether the ...

    Comment?

  20. Not so fast: Phase III Biosimilar Clinical Trial & Infringement...Read the original story

    Monday Dec 8 | Patently Obvious

    ... of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." MedImmune, Inc. v. Genentech, Inc ., 549 U.S. 118, 127 (2007). On appeal, the Federal Circuit affirmed - finding no immediate case or controversy between the ...

    Comment?